PREDICTORS OF CDAI TRAJECTORIES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATACEPT: A REAL-WORLD STUDY

被引：0
|
作者：
Bessette, L. [1 ]
Sampalis, J. [2 ,3 ]
Haraoui, B. [4 ]
Rampakakis, E. [3 ,5 ]
Keating, D. [3 ]
Trepanier, M. O. [6 ]
Pope, J. [7 ,8 ,9 ]
机构：
[1] Laval Univ, Ctr Hosp Univ Laval, Montreal, PQ, Canada
[2] McGill Univ, Fac Med, Montreal, PQ, Canada
[3] JSS Med Res Inc, Montreal, PQ, Canada
[4] Inst Rhumatol Montreal, Montreal, PQ, Canada
[5] McGill Univ, Dept Pediat, Montreal, PQ, Canada
[6] Bristol Myers Squibb, Montreal, PQ, Canada
[7] Western Univ, Dept Med, Div Rheumatol, London, ON, Canada
[8] Western Univ, Dept Med, Div Epidemiol, London, ON, Canada
[9] Western Univ, Dept Med, Div Biostat, London, ON, Canada
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2024年 / 83卷
关键词：
Observational studies/registry; biological DMARD; Patient Reported Outcome Measures;
D O I：
10.1136/annrheumdis-2024-eular.6058
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0634
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
    Hirose, Wataru
    Harigai, Masayoshi
    Amano, Koichi
    Hidaka, Toshihiko
    Itoh, Kenji
    Aoki, Kazutoshi
    Nakashima, Masahiro
    Nagasawa, Hayato
    Komano, Yukiko
    Nanki, Toshihiro
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2022, 6 (03)
  • [2] Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study
    Alten, Rieke
    Mariette, Xavier
    Lorenz, Hanns-Martin
    Nuesslein, Hubert
    Galeazzi, Mauro
    Navarro, Federico
    Chartier, Melanie
    Heitzmann, Julia
    Poncet, Coralie
    Rauch, Christiane
    Le Bars, Manuela
    CLINICAL RHEUMATOLOGY, 2019, 38 (05) : 1413 - 1424
  • [3] Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study
    Rieke Alten
    Xavier Mariette
    Hanns-Martin Lorenz
    Hubert Nüßlein
    Mauro Galeazzi
    Federico Navarro
    Melanie Chartier
    Julia Heitzmann
    Coralie Poncet
    Christiane Rauch
    Manuela Le Bars
    Clinical Rheumatology, 2019, 38 : 1413 - 1424
  • [4] Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study
    Rieke Alten
    Xavier Mariette
    Hanns-Martin Lorenz
    Hubert Nüßlein
    Mauro Galeazzi
    Federico Navarro
    Melanie Chartier
    Julia Heitzmann
    Coralie Poncet
    Christiane Rauch
    Manuela Le Bars
    Clinical Rheumatology, 2019, 38 : 1535 - 1535
  • [5] A COMPARATIVE EFFECTIVENESS STUDY OF ABATACEPT AND TNFI AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING REAL-WORLD DATA
    Alemao, Evo
    Connolly, Sean
    Elbez, Yedid
    Rao, Aarti
    Saini, Yogesh
    Iannaccone, Christine
    Weinblatt, Michael E.
    Shadick, Nancy
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1646 - 1647
  • [6] Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real-world setting in Taiwan
    Chen, Kun-Hung
    Li, Ko-Jen
    Fang, Yao-Fan
    Hsieh, Song-Chou
    Chen, Ying-Chou
    Lee, Chyou-Shen
    Luo, Shue-Fen
    Cheng, Tien-Tsai
    Tsai, Wen Chan
    Lo, Yu-Chen
    Lan, Joung-Liang
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (07)
  • [7] EFFICACY AND SAFETY OF ABATACEPT IN CHINESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: REAL-WORLD DATA
    Qing, Y. F.
    Huang, Q.
    Zhao, Z. Y.
    Zhang, Q. B.
    Li, L. Q.
    Wen, Z.
    You, Z. X.
    Tang, H.
    Xu, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1291 - 1292
  • [8] EPIDEMIOLOGICAL ASSESSMENT OF BASELINE CHARACTERISTICS OF THE ABATACEPT-TREATED PATIENTS IN SELECT REAL-WORLD RHEUMATOID ARTHRITIS DATA SOURCES
    Simon, T.
    Ghandi, K.
    Askling, J.
    Wolfe, F.
    Michaud, K.
    Thyagarajan, V.
    Lin, N.
    van Riel, P.
    van de Laar, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1167 - 1167
  • [9] Real-world observational study of patients with rheumatoid arthritis treated with baricitinib or tofacitinib in a tertiary hospital
    Guillen Benitez, Elena
    Sabate Gallego, Monica
    Ballarin Alins, Elena
    Espartal Lopez, Esther
    Lopez Lasanta, Maria
    Bosch Ferrer, Montserrat
    Artilagas Boixareu, Nuria
    Alerany Pardo, Carmen
    Danes Carreras, Immaculada
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2022, 130 : 16 - 17
  • [10] COMPARATIVE SAFETY OF ABATACEPT IN RHEUMATOID ARTHRITIS WITH COPD: A REAL-WORLD POPULATION-BASED OBSERVATIONAL STUDY
    Suissa, S.
    Ernst, P.
    Dell'Aniello, S.
    Shen, S.
    Simon, T. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 613 - 614
12345